super jili 777 login register
Stock market today: Wall Street drifts lower as it waits for inflation dataHigh school recruiting isn't the only way to build a winner in the transfer portal era
True freshman Jackson Williams delivers 100-yard TD return, sparking Bison playoff victory
Trump vows to block Japanese steelmaker from buying US Steel, pledges tax incentives and tariffs
The York Water Company ( NASDAQ:YORW – Get Free Report ) announced a quarterly dividend on Monday, November 25th, Wall Street Journal reports. Shareholders of record on Tuesday, December 31st will be paid a dividend of 0.2192 per share by the utilities provider on Wednesday, January 15th. This represents a $0.88 dividend on an annualized basis and a yield of 2.66%. The ex-dividend date of this dividend is Tuesday, December 31st. This is a boost from York Water’s previous quarterly dividend of $0.21. York Water has increased its dividend payment by an average of 4.0% annually over the last three years and has raised its dividend every year for the last 27 years. York Water has a dividend payout ratio of 57.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect York Water to earn $1.53 per share next year, which means the company should continue to be able to cover its $0.88 annual dividend with an expected future payout ratio of 57.5%. York Water Price Performance York Water stock opened at $32.95 on Friday. The stock’s 50 day moving average price is $35.38 and its two-hundred day moving average price is $37.17. The stock has a market capitalization of $473.62 million, a price-to-earnings ratio of 22.26 and a beta of 0.63. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.68 and a current ratio of 0.88. York Water has a 52-week low of $32.71 and a 52-week high of $41.96. About York Water The York Water Company impounds, purifies, and distributes drinking water. It owns and operates three wastewater collection systems; ten wastewater collection and treatment systems; and two reservoirs, including Lake Williams and Lake Redman, which hold approximately 2.2 billion gallons of water. The company also operates a 15-mile pipeline from the Susquehanna River to Lake Redman; and owns satellite groundwater systems in York, Adams, and Lancaster Counties, as well as two impounding dams on primary system located in York and Springfield Townships. Featured Stories Receive News & Ratings for York Water Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for York Water and related companies with MarketBeat.com's FREE daily email newsletter .
VANCOUVER - Global Affairs Canada is warning Canadians in South Korea to avoid demonstrations and exercise caution after the country’s president imposed an hours-long period of martial law. The situation in South Korea arose after President Yoon Suk Yeol imposed martial law on Tuesday, vowing to eliminate what he described as “anti-state” forces from the opposition that controls parliament. Yoon’s declaration triggered tense political drama, as troops surrounded the parliament while 190 lawmakers gathered inside to vote to lift the martial law shortly after it was imposed. Global Affairs Canada has not raised the risk level for Canadians in South Korea but did ask those in the country to monitor local media for the latest information, while following authorities’ instructions, such as curfew orders. A Vancouver-based travel agent says the chaos in Seoul is not likely to have a major effect on Canadian visitor numbers to South Korea. Glynnis Chan, owner of Happy Times Travel, says the martial law dissolved quickly and will likely have minimal impact on people’s travel plans, which tend to be made at least two months in advance. “There’s always some sort of impact, but it really depends on what happens with the situation over the long term,” Chan says. “If nothing more happens, people forget after a week or so about what took place.” Chan says she is not expecting any impact on her business, since Japan is a more popular destination among her customers. Several Korean-Canadian travel agencies in Metro Vancouver declined to comment on the political situation in Seoul. After Yoon’s declaration of martial law, hundreds of protesters gathered in front of the national assembly, waving banners and calling for Yoon’s impeachment, while others scuffled with military troops. The South Korean parliamentary members eventually voted to lift the declaration, with national assembly Speaker Woo Won Shik declaring it “invalid.” Police and military personnel were then seen leaving the assembly’s grounds after Woo’s call for their withdrawal. Jae-Yeon Lim, vice-president of the Canada Korea Business Association, says seeing military personnel clash with protesters and lawmakers brought back “harrowing” memories of the 1980 student-led demonstrations in Gwangju that were violently suppressed. Yoon’s move was the first declaration of martial law since the country’s democratization in 1987, and South Korea’s last previous martial law was in October 1979. “It has been a very difficult experience to see that,” Lim says of the latest martial law declaration. “But that said, I’m really happy to see that ... the national assembly managed to get the majority vote to repeal this, and they managed to do that at the risk of their own lives, even though military was there. “This is a country that will stand up for democracy.” Lim also says there would likely be little impact on bilateral relations or trade between the two countries stemming from the sudden onset of political drama, given how quickly martial law was lifted. “It’s not going to stop business from seeking to expand in Canada,” Lim says. “There’s still a very strong interest to do so from many businesses (in South Korea). “We have yet to see what will happen next, but I think that I’m a little bit reassured in seeing what has transpired ... that people are ready to defend their country and democratic rule-of-law.” — With files from The Associated Press This report by The Canadian Press was first published Dec. 3, 2024.None
Even with access to blockbuster obesity drugs, some people don't lose weightWall St indexes fall ahead of inflation data
Fantasy Football Sleepers Week 15: Aaron Rodgers, Kendre Miller, Rome Odunze among breakout picks | Sporting News
US Rep. Brett Guthrie of Kentucky to lead panel overseeing issues affecting daily lives of publicNoneMrBeast and T-Series have finally settled their years-long feud after the label’s CEO met up with the YouTube star in an unexpected collaboration. On December 9, YouTube juggernaut Jimmy ‘MrBeast’ Donaldson linked up with the CEO of T-Series, Bhushan Kumar, in a meeting that no one saw coming. After finally beating out T-Series to become YouTube’s most-subscribed channel in June, Donaldson decided to offer an olive branch to his infamous rival by offering to subscribe to the company’s channel... but only if they subscribed to him first. After jokingly trying to ‘fake out’ Kumar after he subscribed to his channel, he eventually subscribed to T-Series as well, officially putting their feud to rest. Fans await PewDiePie’s response to MrBeast’s T-Series collab However, commenters are divided on this collaboration, with several humorously pointing out that MrBeast has seemingly “betrayed” fellow YouTuber PewDiePie , who he staunchly supported in his viral fight against T-Series back in 2019. “The old MrBeast would be ashamed,” one fan wrote on TikTok. “So it’s treason,” another joked. “We got MrBeast following T-Series before GTA 6,” yet another quipped. Thus far, PewDiePie hasn’t responded to T-Series’ collab with MrBeast, who successfully “avenged” the Swedish creator by surpassing the Indian music label earlier this year. MrBeast was instrumental in PewDiePie’s ‘battle’ against T-Series, even advertising the Swede’s channel at the Super Bowl by wearing shirts that read, “Sub 2 PewDiePie.” Stephen Gostkowski misses the 46-yard FG! pic.twitter.com/jEUct0ObCr But the YouTuber would end up surpassing his idol in 2022, leading PewDiePie to joke that Donaldson should delete his channel as penance. Since then, the two have collaborated together on a video and have remained fast friends. Related: Donaldson’s latest collab with T-Series comes just ahead of his upcoming Amazon game show , Beast Games, which set 28 Guinness World Records and reportedly spent a whopping $14 million on building an entire city for contestants to live in during filming. The show is slated to air on December 19 , with episodes launching weekly in yet another major victory for the internet superstar.
Prosecutors: DC police officer’s talk with Proud Boys leader grew secretive as arrest neared
The Bruins activated depth defenseman Alec Regula from season-opening injured reserve on Tuesday and subsequently placed him on waivers for the purpose of assignment to AHL Providence, Elliotte Friedman of Sportsnet reports. Regula, 24, has yet to play this season after suffering a knee injury over the offseason. It held him out of the entirety of Boston’s training camp and preseason schedule and earned him a non-roster designation when the regular season began. It was an inauspicious start to the 2024-25 campaign for Regula, who spent all of last season in the minors after seeing NHL ice in his previous three professional seasons. Acquired from the Blackhawks in the 2023 Taylor Hall/Nick Foligno trade, Regula led the AHL last season with a +36 rating and added four goals and 26 points in 55 games for Providence, tying his previous career highs. When Regula can expect to touch NHL ice next is anybody’s guess. The 6-foot-4, 211-pound righty made 22 NHL appearances while with Chicago, scoring one goal and logging a -5 rating while averaging 16:54 per game. Initially a 2018 third-round pick of the Red Wings, he’s firmly established himself as a top two-way threat at the AHL level, but has yet to demonstrate marginally positive possession impacts in his NHL minutes. There are likely a few names ahead of Regula who are in line for a recall, namely Ian Mitchell, who leads Providence defenders in scoring with 13 points in 22 games. Whether or not he ends up seeing NHL action during the one-year, two-way deal he inked last summer remains to be seen, but a strong showing in his delayed start to the season should help him at least earn a qualifying offer at season’s end. This article first appeared on Pro Hockey Rumors and was syndicated with permission.Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen
South Korea's president avoids an impeachment attempt over short-lived martial lawDHS Chief Alejandro Mayorkas Announces Jobs Giveaway -- for MigrantsCanadians warned to use caution in South Korea after martial law declared then lifted
- Previous: super ace jili slot machine
- Next: super jili slot casino
